Seed · Biotech · Zurich, Switzerland · Founded 2022 · 8–9 employees
Navignostics is a Swiss precision oncology company founded in 2022 as a spin-off from the University of Zurich's Bodenmiller Lab, specializing in spatial single-cell proteomics to characterize tumors and identify optimal personalized cancer treatments. The company uses multiplex tumor imaging with advanced data analytics to help clinicians select the most effective therapies for individual patients and accelerates cancer drug development through companion diagnostics. It raised CHF 8.5 million and won the Swiss Technology Award 2025 in the Start-ups/Rising Stars category, with plans to launch its first diagnostic product in the Swiss market in 2025 followed by US expansion.
No open roles listed right now.